BioTuesdays

Author - Leonard Zehr

Feature

In conversation with Allen Krantz

By Len Zehr As the founder, president and CEO of Advanced Proteome Therapeutics (TSX-V:APC; Frankfurt:OE8), Dr. Allen Krantz has successfully transitioned a career in academia to the biotech sector. From 1968 to 1974...

January 27, 2015
Feature

EndyMed expands sales effort in U.S.

By Len Zehr After five years of selling its skin rejuvenation devices to medical professionals through a distributor, EndyMed Medical (TASE:ENDY) has launched a U.S.-based direct sales operation through subsidiary...

January 20, 2015
Feature

Season’s Greetings (and JPM 2015)

Wow! What a great year 2014 turned out to be! On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will...

December 19, 2014
Feature

Nuvo Research to release Phase 2 WF10 data in Q1

By Len Zehr Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a game-changing...

December 2, 2014
Feature

rEVO Biologics spearheading preeclampsia treatment

By Len Zehr Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the...

November 11, 2014
Feature

CytoTools awaiting India clearance for DermaPro

By Len Zehr CytoTools AG (DE000A0KFRJ1/T5O) of Germany and its Indian marketing partner, Centaur Pharmaceuticals, expect to receive regulatory clearance in the current quarter in India for lead product, DermaPro, to...

November 4, 2014